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Abstract
Background: Narcolepsy is a chronic sleep disorder with strong genetic predisposition causing excessive daytime sleepiness
and cataplexy. A sudden increase in childhood narcolepsy was observed in Finland soon after pandemic influenza epidemic
and vaccination with ASO3-adjuvanted Pandemrix. No increase was observed in other age groups.
Methods: Retrospective cohort study. From January 1, 2009 to December 31, 2010 we retrospectively followed the cohort of
all children living in Finland and born from January 1991 through December 2005. Vaccination data of the whole population
was obtained from primary health care databases. All new cases with assigned ICD-10 code of narcolepsy were identified
and the medical records reviewed by two experts to classify the diagnosis of narcolepsy according to the Brighton
collaboration criteria. Onset of narcolepsy was defined as the first documented contact to health care because of excessive
daytime sleepiness. The primary follow-up period was restricted to August 15, 2010, the day before media attention on
post-vaccination narcolepsy started.
Findings: Vaccination coverage in the cohort was 75%. Of the 67 confirmed cases of narcolepsy, 46 vaccinated and 7
unvaccinated were included in the primary analysis. The incidence of narcolepsy was 9.0 in the vaccinated as compared to
0.7/100,000 person years in the unvaccinated individuals, the rate ratio being 12.7 (95% confidence interval 6.1–30.8). The
vaccine-attributable risk of developing narcolepsy was 1:16,000 vaccinated 4 to 19-year-olds (95% confidence interval
1:13,000–1:21,000).
Conclusions: Pandemrix vaccine contributed to the onset of narcolepsy among those 4 to 19 years old during the pandemic
influenza in 2009–2010 in Finland. Further studies are needed to determine whether this observation exists in other
populations and to elucidate potential underlying immunological mechanism. The role of the adjuvant in particular
warrants further research before drawing conclusions about the use of adjuvanted pandemic vaccines in the future.
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Introduction
To protect the population from death and serious forms of
disease caused by the pandemic AH1N1 infection, the ASO3
adjuvanted vaccine Pandemrix was introduced nation-wide in
Finland from October 2009 onwards according to the strategic
prioritization order (Table 1) [1]. No other pandemic vaccines
were available in the country. Vaccination was carried out as soon
as the vaccines arrived in the country, starting 12th October 2009.
Following recommendation of the European Medicines Agency
(EMA), enhanced passive surveillance of vaccine related adverse
events was initiated. Excess number of narcolepsy-cataplexy
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33536among children and adolescents was observed a few months after
the A(H1N1) epidemic and pandemic vaccination [2]. Narcolepsy
was not among the sentinel events EMA encouraged to be
followed.
Narcolepsy, a rare neurological sleep disorder characterized by
excessive daytime sleepiness (EDS) and cataplexy, has never before
the A(H1N1) pandemic been reported in association with
vaccination [3,4]. The cause of narcolepsy is unknown. Immuno-
logical mechanisms are considered instrumental to the onset of
narcolepsy in genetically susceptible persons [5–7]. In addition,
environmental factors capable of modulating immune system, e.g.
streptococcal A and viral infections, have been suggested to trigger
or accelerate disease development [6,8–14].
To evaluate the observed safety signal suggesting association
between Pandemrix vaccination and abrupt manifestation of
narcolepsy in childhood and adolescence [1,2], we first estimated
the incidence of narcolepsy from register data and then performed
a population based retrospective cohort study to verify the signal
and to characterize its association with the pandemic vaccination.
Methods
The study was done in Finland, a Northern European country
with a population of 5.3 million and an annual birth cohort of
approximately 60,000.
Study population
The Finnish Population Information System, a computerised
national register, allowed us to scrutinize the entire population.
Personal data including name, gender, personal identity code,
address, date of birth and death of all residents are recorded in this
register. The personal identity code remains unchanged through-
out a person’s lifetime.
Exposure to Pandemrix vaccination
Finnish municipalities (local governments) are responsible for the
primary health care and subsequently the administration of the
vaccines for the citizens in their region. Vaccinations with Pandemrix
of those 19 years and below almost exclusively took place between
weeks 44–52, 2009 (Figure 1), and were recorded in the electronic
primary health care databases, which are linked to the Population
Information System.Personal identitycodesof the vaccinees and dates
of vaccinations administered up till September 2010 were retrieved
from these databases. The completeness of the exposure data was
investigated by reviewing vaccination records of 1000 individuals that
were randomly selected from the Population Information System.
Screening of narcolepsy
Information on visits and hospitalizations assigned ICD-10 code
G47.4 was obtained from the national care register covering all
care provided in the Finnish hospitals for the years 1999–2009 and
from the local hospital care registers for the year 2010. The same
search was done in registers of the three specialized health care
centers known to have the capacity of making the diagnosis of
narcolepsy. The first recorded date was regarded as the date of
diagnosis for that particular individual with narcolepsy. Incident
cases of narcolepsy were calculated for the years 2009–2010 by
using hereby determined dates of diagnosis assuming that if G47.4
was recorded for the first time in 2009 or later in the data
representing years 1999–2010, it truly was the time when the
diagnosis was set.
Retrospective cohort study in the subgroup with
increased incidence of narcolepsy
Having established that the increase in the incidence of
narcolepsy occurred solely in the age group between 4–19 years
[1,2], we designed a retrospective cohort study of all children born
during the period from January 1, 1991, to December 31, 2005
and living in Finland at any time during the years 2009–10. The
primary follow-up period for this cohort started on January 1,
2009 and ended on August 15, 2010, the day before media
attention on post-vaccination narcolepsy started in Finland.
Special attention was paid to case ascertainment and determin-
ing disease onset. All the relevant records of the ICD-10 G47.4-
coded new patients belonging to the cohort and diagnosed during
2009–10 were reviewed [2]. Two narcolepsy experts (MP, TKir)
independently reviewed the patient records and classified the cases
according to the Brighton Collaboration criteria for diagnostic
accuracy (Level 1, Level 2, Level 3, Unknown, or Not a case; work
in progress www.brightoncollaboration.org, Table 2), The criteria
are an extension of the American Academy of Sleep Medicine
criteria for narcolepsy with added estimation of the reliability of
the diagnosis. In the discrepant cases, the final level of diagnosis
was set by a panel of three other narcolepsy experts (SLH, PO
alternating with CH, OSH). A case was considered narcoleptic in
the primary analysis, if it was classified as Level 1–3.
In the primary analysis, the onset of narcolepsy was defined as
the day when for the first time a school nurse, medical practitioner
or other health care professional attended the patient because of
the parental or own complaint of EDS, and recorded the
observation in the patient records. This was considered the
earliest objective time point available to define the onset time, and
unlike the other time points available, less susceptible to the impact
Table 1. The prioritization order of the pandemic influenza vaccinations in Finland during the A(H1N1) pandemic recommended
by the National Advisory Committee on Vaccinations.
1. Social and health care professionals who work with A(H1N1) infected patients or patients presumably exposed to the infection, as well as
ambulance personnel, and pharmacists who work in customer service
2. Pregnant women
3. People aged 6 months to 64 years at high risk due to their underlying illness. This category includes persons who require regular medication for
heart or lung disease, metabolic disease, chronic liver or kidney disease, immune deficiency because of an underlying condition or treatment,
chronic neurological disease or neuromuscular disease
4. Healthy children from 6 to 35 months of age
5. Healthy children and adolescents from 3 to 24 years of age as well as army conscripts
6. People aged 65 years and above who belong to high risk group due to an underlying illness. After this
7. The rest of the population
doi:10.1371/journal.pone.0033536.t001
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press release on narcolepsy after Pandemrix vaccination given out
by the Swedish Medical Authorities.
In the sensitivity analyses, three additional onset times were
used, also to allow for comparison with earlier register data and
with other studies.
Patient or parental recall. The two reviewers (MP, TKir)
gave independent estimates of the onset time of symptoms (EDS
and/or cataplexy) by reviewing the patient records. The patient or
parental report of the time of onset usually had been recorded at
the time of diagnostic workup. The mean date of these two
estimates was used in the analysis.
Referral. The date of referral to a pediatrician or pediatric
neurologist was the day when the attending clinician wrote a
request of referral to a specialist.
Diagnosis. The date of diagnosis was defined as the date
when the ICD code G47.4 was for the first time noted in the
patient records.
Statistical methods
The incidence of narcolepsy after exposure to H1N1 vaccina-
tion was compared to the incidence of narcolepsy without
exposure to H1N1 vaccination using Poisson regression. Pandemic
vaccination was treated as a time-dependent covariate meaning
that subjects moved over from the unexposed state to the exposed
state at the time of vaccination. Narcolepsy cases were grouped by
vaccination status at the time of disease onset and the person times
of the cohort in the vaccinated and unvaccinated states were used
as weights in the analysis. The total person time in the cohort was
calculated based on aggregate numbers of individuals by sex, year
of birth, and region at the turn of 2009/2010 (immigration and
emigration in the age group 4 to 19-year-olds in Finland is less
than 0.3%). Person time in the vaccinated state was calculated
based on weekly cumulative aggregates of the vaccinated during
the follow-up. The results are expressed as the rate ratio with 95%
confidence intervals based on profile likelihood. The relative rate
was calculated by comparing incidences in the vaccinated and
unvaccinated states during the follow-up in question. Absolute
incidences were calculated by number of narcolepsy cases divided
by the person times in the population in the respective states
(vaccinated/unvaccinated). The vaccine attributable risk was
calculated as the cumulative incidence in the vaccinated minus
the expected cumulative incidence without vaccination during the
same follow-up time.
Figure 1. The temporal associations of pandemic vaccination, onset of narcolepsy (with four different definitions), and August 16,
2010, i.e. the date when the Swedish Medical Agency published the press release on the observation on the association between
narcolepsy and Pandemrix vaccination (vertical dotted line). Panel top left is Recall=Parental/Patient recall when excessive daytime
sleepiness (EDS) started; Panel top right is First contact=first contact to health care because of EDS; Panel bottom left is Referral=referral to specialist
(paediatrician, neurologist); and Panel bottom right is Diagnosis=when diagnosis of narcolepsy was set.
doi:10.1371/journal.pone.0033536.g001
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was used to pinpoint disease onset, and the follow-up time was
from January 1st 2009 until August 15th 2010. The follow-up in
the primary analysis started 10 months prior to the vaccination
campaign. This was done in order to obtain information about the
baseline incidence and to aqcuire more power to estimate the risk
in the unvaccinated. Several sensitivity analyses using different
onset definitions and follow-up times were conducted to investigate
changes in the risk of the unvaccinated in calendar time, and bias
potentially introduced by the increasing awareness among the
health care workers and the public of the suspicion that there was
a link between Pandemrix and narcolepsy. To minimize potential
detection bias, follow-up periods ending as early as February 22,
2010 were also tested. This was the date when one of the authors
(MP) for the first time raised the question of the association of one
of the cases and H1N1 infection in a discussion between
colleagues.
Ethics statement
The study protocol was reviewed and approved by the
Institutional Review Board of the National Institute for Health
and Welfare (THL), Finland.
Results
Vaccination coverage in the population
In total, 2,76 million Pandemrix vaccine doses were given
between October 2009 and August 2010. Vaccination coverage
across the country was 52%, but varied from 32 to 82% in the
different age groups (Table 3). In contrast, the geographical
variability measured as variability across the 21 hospital districts of
the country was low, particularly in children and adolescents
ranging from 64 to 81%. Of the 915,854 individuals born between
1991 and 2005, 688,566 (75%) were vaccinated. All vaccinated
individuals had received only one dose as recommended. The
review of the vaccination records of the randomly selected 1000
individuals belonging to the study cohort revealed discrepancy
between the local health care records and the electronic register
data in four cases, all of whom had been vaccinated according to
record review but not according to the database search. In
addition to the sample of 1000, the vaccination records of all newly
diagnosed narcolepsy cases born between 1991 and 2009 were also
reviewed. No discrepancies were found.
Patients with confirmed diagnosis in the retrospective
cohort
Altogether 71 new diagnoses of narcolepsy were set in children
and adolescents aged 4 to 19 years of age in 2009–10 according to
the G47.4 ICD10 code. Medical records were obtained from all.
Based on the expert review of the hospital and primary care
records, the diagnosis of narcolepsy was classified as being level 1
in 11 (16%), level 2 in 51 (76%), and level 3 in 5 (8%) of the
patients according to the Brighton collaboration definitions. The
two reviewers differed in their opinion on level of classification in
three cases. In full agreement by the reviewers, four cases were
classified as unknown or not a case. Of the 67 confirmed cases, 57
(85%) sought medical care and 61 (91%) received the diagnosis
after pandemic vaccination. Thirty-three were female, 34 male. A
detailed clinical description of the patients constituting most of the
cohort of narcoleptic cases seen in 2010 has been provided
elsewhere [2].
Twenty of the first health care contacts were documented in
school medical records, 21 in health centres, 8 in private practice,
and the rest in hospitals. The time elapsed from vaccination to the
onset of disease varied depending on the definition used for onset
(Figure 2). Eighteen children were referred to a specialist already
after Christmas 2009 and prior to the end of February 2010, 15
children were referred between 1 March 2010 to 15 August 2010,
prior to the media attention, and 27 on or shortly after this date
(Figure 2). The effect of the media attention shows as a bimodal
Table 2. Brighton collaboration criteria for diagnostic
accuracy of narcolepsy.
Level The Brighton collaboration criteria
Level 1
In the presence of
criterion 1 Excessive daytime sleepiness and/or definite cataplexy,
AND
criterion 2 CSF hypocretin-1 deficiency
Level 2
In the presence of
criterion 1 Excessive daytime sleepiness, AND
criterion 2 Definite cataplexy, AND
criterion 3 Level 1 or 2 Multiple Sleep Test (MSLT) abormalities
Level 3
In the presence of
criterion 1 Excessive daytime sleepiness, AND
criterion 2 Level 1 MSLT abnormalities
In the absence of Other mimicking disorders
doi:10.1371/journal.pone.0033536.t002
Table 3. The age-specific Pandemic vaccination coverage in
Finland during the influenza pandemic season in 2009–10.
Age group N vaccinated
1 N total
2 Percentage
0–4 221,297 298,114 74.2
5–9 232,023 287,786 80.6
10–14 247,720 302,423 81.9
15–19 189,247 334,636 56.6
20–24 104,535 324,472 32.2
25–29 109,387 344,634 31.7
30–34 133,026 337,970 39.4
35–39 130,096 310,768 41.9
40–44 149,077 358,754 41.6
45–49 160,040 378,341 42.3
50–54 168,853 378,037 44.7
55–59 189,854 388,165 48.9
60–64 220,640 396,886 55.6
65–69 149,071 258,319 57.7
70–74 131,876 225,043 58.6
75–79 101,793 179,671 56.7
80- 122,791 247,408 49.6
Total 2,761,326 5,351,427 51.6
Sources:
1Electronic patient records in Finnish health care centres.
2Population register of Finland;
doi:10.1371/journal.pone.0033536.t003
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panels top right and bottom left; Figure 2). The delay from referral
to the diagnosis was generally shorter for those referred on or after
August 16, 2010 than before (mean delay 42 vs.122 days). The
vaccinated patients were younger than those unvaccinated
(Figure 3). Geographically, cases occurred in 16/21 Finnish
hospital districts. This is in accordance with the underlying
population size.
In the primary analysis, the incidence of narcolepsy was 9.0 in
the vaccinated as compared to 0.7/100,000 person years in the
unvaccinated children and adolescents, translating into a rate ratio
of 12.7 (95% confidence interval 6.1–30.8) (Table 4). The lower
limit of the 95% confidence level of the rate ratio was well above
one in all sensitivity analyses using different follow-up periods and
onset time definitions, except for the date of diagnosis as onset
definition and follow-up period ending February 22, 2010
(Figure 4).
Six cases of narcolepsy had their first health care contact prior
to the first H1N1 epidemic and the vaccination campaign. During
the prepandemic and prevaccination follow-up period from
January to October 2009, the baseline incidence of narcolepsy
in the age-group of 4–19-year-olds was estimated as 0.79/100,000
person-years. No obvious change in the rate of unvaccinated was
observed after the start of the campaign: By the time of media
attention in August 2010, one case was recorded in the 227,288
unvaccinated, compared to an expected of 1.8 cases. With the
estimated incidence in the vaccinated (9.0/100,000 person-years),
one would have expected 20.6 unvaccinated cases.
Based on the primary analysis, the vaccine attributable risk of
developing narcolepsy within approximately 8 months after
Pandemrix vaccination was estimated to be 1 in 16,000, with
95% confidence interval from 1 in 13,000 to 1 in 21,000
vaccinated.
Discussion
We found a 12.7-fold risk of narcolepsy in 4–19-year-old
individuals within approximately 8 months after Pandemrix
vaccination as compared to unvaccinated individuals in the same
age group. This translates into a vaccine attributable risk of
1:16,000.
Our study covers the entire population of Finland and is based
on comprehensive data on individual Pandemrix vaccinations,
diagnoses of narcolepsy and linkage of the two using unique
Figure 2. The different time intervals from the vaccination to the onset of narcolepsy depending on the definition of the onset time
point, i.e. a) estimated onset time based on the extensive review of the patient records by a sleep and/or narcolepsy specialist, and
closest to the parental/patient recall; b) first recorded contact to health care because of excessive sleepiness; c) date of referral to
paediatrician or pediatric neurologist; and d) date of setting the diagnosis of narcolepsy, ICD-10 G47.4.
doi:10.1371/journal.pone.0033536.g002
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Vaccination records were retrieved from primary health care
databases. The high accuracy of the exposure data was confirmed
through a validation check on a random sample. Newly diagnosed
cases of narcolepsy were identified via a systematic nationwide
search from the hospital registers, and the diagnoses were verified
through a systematic stepwise expert review procedure.
Some parents may have been tempted to recall the onset of
symptoms as occurring after, rather than before their child
received the pandemic vaccine. Therefore, we used different
definitions for disease onset to evaluate the significance of the
timing of onset on the observed association. In the primary
analysis, the earliest note of EDS in the patient’s medical records
was used to limit recall bias.
A particular concern is that the observed association is a result
of increased detection of narcolepsy among vaccinated children.
According to such a view, a similar increase in narcolepsy among
unvaccinated children has occurred but is yet to be observed.
This argument, however, is not supported by the factual
circumstances. In early 2010, narcolepsy was a rare disease
unknown to most parents. Also, very few primary care physicians
had seen a narcoleptic child, and no beliefs, even less conviction
associated narcolepsy with the pandemic vaccine. Yet consider-
able numbers of Pandemrix vaccinated children were already
referred to specialist before the end of February 2010 and later
diagnosed with narcolepsy. The sudden surge of referrals during
the first months of 2010 can hardly be explained by increased
awareness and changes in diagnostic practices alone. Awareness
was aroused and referrals to specialist and diagnostic workup
expedited only after the media attention from Sweden broke out
in August 2010.
Should a confounding factor instead of vaccination be the true
cause of the association, it would have to be even more strongly
associated with narcolepsy than the pandemic vaccination as we
now report. In addition, such a risk factor should have a strong
and time dependent positive correlation with the vaccination itself.
A recent study in China found a 3–4-fold greater than predicted
occurrence of narcolepsy onset following the 2009–10 H1N1
pandemic season, which was independent of vaccination [14]. In
our study, there was no evidence of change in the incidence among
the unvaccinated 4–19-year-olds after the first H1N1 epidemic in
Finland, whereas a considerably increased risk was associated with
vaccination. As H1N1 infection was hardly more common in the
vaccinated than in the unvaccinated population, our findings
Figure 3. The age distribution of the new narcoleptic cases among the Pandemrix vaccinated and unvaccinated children and
adolescents. Age presented in years.
doi:10.1371/journal.pone.0033536.g003
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infectious, environmental, social or psychological factors that
could modify the strength of the association seen in this study but
none that could completely undo an association of this magnitude.
Our finding is supported by the recent results from Sweden,
where a cohort study covering the entire population reported an
almost 7-fold incidence of narcolepsy with cataplexy in children
vaccinated with Pandemrix compared to those in the same age
Table 4. Main results of the cohort analysis using two follow-up periods among those born at or after 1 January 1991.
Incidence in confirmed narcolepsy cases
Follow-up period Narcolepsy cases Follow-up years Relative Risk
Not vaccinated Vaccinated Not vaccinated Vaccinated Risk ratio 95%LCL 95%UCL
First contact:
2009-01-01 to
2010-12-31
7 57 1,069,247 762,461 11.4 5.6 27.5
First contact:
2009-01-01 to
2010-08-16
1
7 46 986,195 510,874 12.7 6.1 30.8
1The date when the news on the possible association between narcolepsy and Pandemrix vaccination observed in Sweden was published in the national mediai n
Finland.
LCL=Lower confidence limit, UCL=Upper confidence limit.
doi:10.1371/journal.pone.0033536.t004
Figure 4. Sensitivity analyses of the risk ratio of Pandemrix vaccination and narcolepsy using different definitions of the onset
dates of narcolepsy and follow-up time periods. The two intervals in the top left panel are missing because of infinite estimates (i.e. no cases
among unvaccinated).
doi:10.1371/journal.pone.0033536.g004
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unvaccinated (0.64/100,000 person-years) compares well to that
seen in our study. Preliminary passive reporting system data from
France, Norway and Ireland also indicate higher than expected
number of cases in children and adolescents after Pandemrix
vaccination [15–17]. On the other hand, it is perplexing that both
Canada and the United Kingdom lack the signal. In these two
countries, genetic susceptibility to narcolepsy is as common as in
the Nordic countries. This suggests multifactorial nature of the
observed phenomenon.
The biological plausibility for a vaccine contributing to the
increased risk of narcolepsy particularly in the signal-generating
age group is based firstly on the immunomodulatory effects of
vaccination and secondly on the fact that narcolepsy is strongly
linked to the HLA DQB1*0602 allele [18]. An analogous example
of a similar disease process affecting children and adolescents in
particular is provided by type 1 diabetes, in which insulin-
producing beta-cells are destroyed by immunological mechanisms
in genetically predisposed individuals with HLA DQB1*0302 and
02 alleles [19–21]. Neither an increase nor an imbalance between
the vaccinated and unvaccinated in the incidence of narcolepsy
was seen in the population older than 19 years [2]. It is noteworthy
that the HLA DQB1*0602 allele is approximately twice as
common in northern than in southern Europe [22] and that apart
from the Nordic countries, Ireland and Canada, the AS03
adjuvanted vaccine was not widely used in the age group from 4
to 19 years. It should therefore not be surprising that the signal was
detected in Sweden and Finland.
Vaccinations may induce bystander activation of immunological
responses especially due to function of adjuvants. The age-related
differences in the immune responsiveness to Pandemrix vaccina-
tion may be of importance in the induction of the bystander
activation of immune system [23]. Pandemrix vaccination could
have accelerated an on-going disease process rather than triggered
narcolepsy associated autoimmunity. As computer search for
peptide homologies between H1N1 virus and neuron-specific
proteins did not reveal any potential molecular mimicry [7,24–27],
it seems unlikely that H1N1 virus infection or vaccination induced
cross-reactive autoimmunity against hypocretine-producing neu-
rons.
Our finding raises concerns of lipid containing adjuvants.
Animal models have suggested that squalene, although at higher
doses than used in human vaccines, is capable of contributing to
the development of autoimmunity [28–30]. In humans, the
epidemiological data available until now has not supported the
induction of autoimmunity by squalene containing adjuvants.
Adjuvanted vaccines are much needed to enhance immune
responses, especially in immune compromised persons. The large
scale use of new adjuvanted vaccines in human populations calls
for further research of their association with adverse effects, such
as autoimmunity.
Further studies are urgently needed to determine whether the
association between adjuvanted pandemic vaccinations and
narcolepsy can be demonstrated in other populations. The
underlying immunological mechanism also warrants further
research.
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